MY160979A - A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders - Google Patents

A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Info

Publication number
MY160979A
MY160979A MYPI2013000225A MYPI2013000225A MY160979A MY 160979 A MY160979 A MY 160979A MY PI2013000225 A MYPI2013000225 A MY PI2013000225A MY PI2013000225 A MYPI2013000225 A MY PI2013000225A MY 160979 A MY160979 A MY 160979A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
metabolic disorders
methods
treating diabetes
combination pharmaceutical
Prior art date
Application number
MYPI2013000225A
Other languages
English (en)
Inventor
Oleg Lliich Epshtein
Original Assignee
Oleg Llich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY160979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Oleg Llich Epshtein filed Critical Oleg Llich Epshtein
Publication of MY160979A publication Critical patent/MY160979A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2013000225A 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders MY160979A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами

Publications (1)

Publication Number Publication Date
MY160979A true MY160979A (en) 2017-03-31

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013000225A MY160979A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Country Status (30)

Country Link
US (1) US8617555B2 (cg-RX-API-DMAC7.html)
EP (2) EP2595658A2 (cg-RX-API-DMAC7.html)
JP (2) JP2013533268A (cg-RX-API-DMAC7.html)
KR (2) KR20180127515A (cg-RX-API-DMAC7.html)
CN (1) CN103118707A (cg-RX-API-DMAC7.html)
AR (1) AR082312A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011281240B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013001299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2805961A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000200A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2013124A3 (cg-RX-API-DMAC7.html)
DE (1) DE112011102396T5 (cg-RX-API-DMAC7.html)
DK (1) DK201370089A (cg-RX-API-DMAC7.html)
EA (1) EA029847B1 (cg-RX-API-DMAC7.html)
EE (1) EE05761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2445846R1 (cg-RX-API-DMAC7.html)
FI (1) FI20135152L (cg-RX-API-DMAC7.html)
FR (1) FR2962913A1 (cg-RX-API-DMAC7.html)
GB (2) GB2552405B (cg-RX-API-DMAC7.html)
IT (1) ITTO20110627A1 (cg-RX-API-DMAC7.html)
LT (1) LT5980B (cg-RX-API-DMAC7.html)
MX (1) MX2013000804A (cg-RX-API-DMAC7.html)
MY (1) MY160979A (cg-RX-API-DMAC7.html)
NO (1) NO20130265A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ606964A (cg-RX-API-DMAC7.html)
PE (1) PE20130815A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500140A1 (cg-RX-API-DMAC7.html)
SE (1) SE1350212A1 (cg-RX-API-DMAC7.html)
SG (1) SG187578A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012010966A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
AU2003262804A1 (en) * 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
MXPA06008180A (es) * 2004-01-20 2006-08-31 Astellas Pharma Inc Metodo para tratar disfuncion erectil.
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) * 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) * 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria

Also Published As

Publication number Publication date
KR20180127515A (ko) 2018-11-28
EA201300124A1 (ru) 2013-12-30
LT5980B (lt) 2013-12-27
SG187578A1 (en) 2013-03-28
WO2012010966A2 (en) 2012-01-26
CZ2013124A3 (cs) 2013-06-12
PH12013500140A1 (en) 2013-03-11
US20130064824A1 (en) 2013-03-14
KR20130103486A (ko) 2013-09-23
GB2496799A (en) 2013-05-22
MX2013000804A (es) 2013-10-28
JP2013533268A (ja) 2013-08-22
ITTO20110627A1 (it) 2012-01-22
AR082312A1 (es) 2012-11-28
DE112011102396T5 (de) 2013-05-02
GB201707872D0 (en) 2017-06-28
NO20130265A1 (no) 2013-04-18
FR2962913A1 (fr) 2012-01-27
FI20135152A7 (fi) 2013-02-21
EA029847B1 (ru) 2018-05-31
DK201370089A (en) 2013-02-19
CL2013000200A1 (es) 2015-01-23
EE05761B1 (et) 2016-03-15
LT2013018A (lt) 2013-10-25
AU2011281240A1 (en) 2013-03-07
US8617555B2 (en) 2013-12-31
GB2552405A (en) 2018-01-24
JP2016222684A (ja) 2016-12-28
ES2445846R1 (es) 2015-01-02
CA2805961A1 (en) 2012-01-26
GB2552405B (en) 2018-05-30
SE1350212A1 (sv) 2013-04-22
GB201302924D0 (en) 2013-04-03
ES2445846A2 (es) 2014-03-05
AU2011281240B2 (en) 2016-07-07
EP3693018A1 (en) 2020-08-12
CN103118707A (zh) 2013-05-22
PE20130815A1 (es) 2013-07-18
BR112013001299A2 (pt) 2017-11-21
WO2012010966A3 (en) 2012-03-29
NZ606964A (en) 2015-08-28
EE201300007A (et) 2013-08-15
EP2595658A2 (en) 2013-05-29
GB2496799B (en) 2017-11-22
FI20135152L (fi) 2013-02-21

Similar Documents

Publication Publication Date Title
MY160979A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2015008114A (es) Derivados de exendina-4.
MX2014003579A (es) Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
FI20135146A7 (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
GEP20156319B (en) Asymmetric ureas and medical uses thereof
SG10201803778PA (en) Treatment for rheumatoid arthritis
NZ598722A (en) Methods for treating psoriasis
GB2496795A (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
AU2010286532A8 (en) Methods of treatment using anti-oxidized LDL antibodies
AU2012334804A8 (en) Modulators of C3a receptors
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
UA112981C2 (uk) Варіант людського gdnf
UA35015U (ru) Способ иммунореабилитации больных метаболическим синдромом
UA64829U (ru) Способ медицинской реабилитации больных послеродовыми психозами
UA97535C2 (ru) Лекарственный противоэпилептический препарат леветирацетама в форме таблеток, способ его изготовления и кристаллический состав
UA53455U (ru) Способ лечения некоторых дерматозов